Laboratory Tests for Diagnosing Hyperparathyroidism
The diagnosis of hyperparathyroidism requires simultaneous measurement of serum calcium and intact parathyroid hormone (iPTH) as the essential laboratory tests. 1
Core Diagnostic Tests
- Serum calcium (total calcium corrected for albumin) and intact parathyroid hormone (iPTH) should be measured simultaneously to establish the diagnosis 1, 2
- Serum phosphate levels should be measured as hyperparathyroidism typically causes hypophosphatemia 2
- 25-hydroxyvitamin D levels must be assessed to exclude vitamin D deficiency as a secondary cause of elevated PTH 3, 2
- Serum creatinine and blood urea nitrogen (BUN) to evaluate kidney function, as hypercalcemia can affect renal function 3
- Urine calcium/creatinine ratio in a random spot urine to assess for hypercalciuria 3
Diagnostic Algorithm
Initial screening: Measure serum calcium (corrected for albumin) and iPTH simultaneously 1
Additional tests to confirm diagnosis:
- Serum phosphate (typically low in primary hyperparathyroidism) 2
- Calcium-to-creatinine clearance ratio (to rule out familial hypocalciuric hypercalcemia if ratio <0.01) 5
- 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels 3, 5
- Serum chloride (chloride/phosphate ratio >33 suggests primary hyperparathyroidism) 5
Special Considerations
- Use assay-specific reference ranges for PTH, as different assay generations measure different PTH fragments 2, 3
- Be aware that vitamin D deficiency can coexist with and complicate the diagnosis of hyperparathyroidism 3
- Consider factors that can affect calcium and PTH levels:
Atypical Presentations
- Normocalcemic hyperparathyroidism: Normal calcium with elevated PTH (after excluding secondary causes) 6, 7
- Normohormonal hyperparathyroidism: Elevated calcium with PTH in the normal range 6
- In cases where both calcium and PTH are within reference ranges but hyperparathyroidism is suspected, a calcium-PTH nomogram may help distinguish between normal patients and those with atypical primary hyperparathyroidism 6
Monitoring Parameters
- For patients on treatment for secondary hyperparathyroidism, monitor serum calcium and phosphorus monthly for the first 3 months, then every 3 months thereafter 3
- Serial assessments of phosphate, calcium, and PTH levels should be considered together for ongoing management 3
Common Pitfalls to Avoid
- Not assessing vitamin D status when interpreting PTH levels 3
- Using different PTH assay generations without considering their varying sensitivity to PTH fragments 2, 3
- Failing to correct calcium for albumin levels 1
- Not considering familial hypocalciuric hypercalcemia in patients with hypercalcemia, normal/elevated PTH, and low urinary calcium excretion 5